¼¼°èÀÇ ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® - Á¦Ç°º°, À¯Åë ä³Îº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Senolytics And Anti-Aging Pharmaceuticals Market Size, Share & Trends Analysis Report By Product (Anti-Aging Pharmaceuticals), By Distribution Channel, By Application (Clinical Use / Off-label Therapeutics), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1726251
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,242,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,627,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,398,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 63¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È CAGR 7.59%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â °í·ÉÈ­ Àα¸¿Í Æò±Õ ¼ö¸í Áõ°¡, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ¾Ï, ´ç´¢º´, °ñ´Ù°øÁõ µî ³ë³â Àα¸¿¡¼­ ¹ß°ßµÇ´Â ºñÀü¿°¼º ÁúȯÀÇ À¯º´·ü »ó½ÂÀÌ Æ÷ÇԵ˴ϴÙ. ³ëÈ­ ¹æÁö ÀǾàǰ¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í¿Í ÀÌµé ³ëÀοëÇØ¼º ÀǾàǰÀÇ Ã¤¿ë·ü »ó½ÂÀÌ ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¶ÇÇÑ °­·ÂÇÑ ¿¬±¸°³¹ß ÅõÀÚ¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¼ö¸¹Àº Á¦¾à ±â¾÷À̳ª Çмú ±â°üÀÌ, ³ëÈ­ ¹æÁö ¿ä¹ýÀÇ °³¹ß, ÀÓ»ó ½ÃÇèÀÇ ÁøÀü, ³ëÈ­ ¼¼Æ÷¸¦ È¿°úÀûÀ¸·Î Ç¥ÀûÀ¸·Î ÇÏ´Â ¹æ¹ý¿¡ °üÇÑ Áö½ÄÀÇ È®´ë¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á, Áٱ⼼Æ÷ Ä¡·á, ¸é¿ªÁ¶ÀýÁ¦ ¿¬±¸°¡ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖ¾î ½ÃÀå ÆÄÀÌÇÁ¶óÀÎÀº ¿©ÀüÈ÷ źźÇÕ´Ï´Ù.

2025³â 2¿ù, ³ëÈ­¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ½Å±Ô Ÿ°ÙÀÎ FOXO4-DRI ÆéƼµå°¡ Çõ½ÅÀûÀ¸·Î ¹ß°ßµÇ¾ú½À´Ï´Ù. ÀÌ ÇÕ¼º ÆéŸÀ̵å´Â FOXO4¿Í p53 ´Ü¹éÁúÀÇ »óÈ£ÀÛ¿ëÀ» ÀúÇØÇÏ°í ³ëÈ­ ¼¼Æ÷ÀÇ ¾ÆÆüÅä½Ã½º¸¦ À¯µµÇÕ´Ï´Ù. µ¿¹° ¸ðµ¨¿¡¼­ÀÇ ¿¬±¸¸¦ ÅëÇØ ½ÅºÎÀüÀ̳ª Çã¾à µîÀÇ ³ëÈ­¿Í °ü·ÃµÈ Áõ»óÀ» ¿ÏÈ­ÇÒ °¡´É¼ºÀÌ ³ªÅ¸³µ½À´Ï´Ù. ÀÌ ½Å±Ô Ÿ°Ù¿¡ ´ëÇØ in vitro ¹× in vivo ¿¬±¸°¡ ÁøÇàµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Áö½ÄÀº FOXO4-DRI°¡ ³ëÈ­ ¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÇÏ¿© ³ëÈ­¿Í °ü·ÃµÈ º´Å¸¦ ¿ÏÈ­ÇÏ´Â Ä¡·á °¡´É¼ºÀ» °¡Áö°í ÀÖÀ½À» ½Ã»çÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ 2025³â 2¿ù¿¡´Â ÇÁ·ÎÅ׿À¶óÀ̽ýº Ç¥Àû Ű¸Þ¶ó(PROTAC)·Î ¾Ë·ÁÁø ¶Ç ´Ù¸¥ ½Å±Ô ³ëÈ­ ¼¼Æ÷ Ç¥Àû ºÐÀÚ°¡ °³¹ßµÇ¾ú½À´Ï´Ù. PROTAC´Â ƯÁ¤ ´Ü¹éÁúÀ» E3 ¸®°¡¾ÆÁ¦¿¡ °áÇÕ½ÃÄÑ À¯ºñÄûƾȭÇϰí ÇÁ·ÎÅ×¾ÆÁ» ºÐÇØ·Î ÀεµÇÔÀ¸·Î½á ´Ü¹éÁú ºÐÇØ¸¦ À¯µµÇÏ´Â 2±â´É¼º ºÐÀÚÀÔ´Ï´Ù. ¼¼Æ÷ ³ëÈ­ÀÇ ¸Æ¶ô¿¡¼­´Â BCL-xL/BCL-2 ºÐÇØ³ª BRD4 ºÐÇØ µîÀÇ ¸ÞÄ¿´ÏÁòÀ» ÅëÇØ ³ëÈ­ ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î Á¦°ÅÇϴ ƯÁ¤ PROTAC°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¡¿¡¼­ ³ëÈ­ ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î Ç¥ÀûÀ¸·Î ÇÏ¿© ¹èÁ¦ÇÏ´Â PROTACÀÇ Ä¡·áÀû °¡´É¼ºÀÌ °­Á¶µÇ¾î ³ëÈ­ °ü·Ã ÁúȯÀÇ Ä¡·á³ª °Ç°­ ¼ö¸íÀÇ °³¼±¿¡ À¯¸ÁÇÑ Àü·«À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

°Ô´Ù°¡, ¼¼Æ÷¿Ü ¼ÒÆ÷(EV)¿Í miRNA¿¡ ±âÃÊÇÑ ¼¼³ë¸®Æ½½º ±â¼ú¿¡ ´ëÇÑ Ã¶ÀúÇÑ Á¶»ç°¡ ¾à¹°À» ÀÓ»ó½ÃÇè¿¡ ¹ÝÀÔÇϱâ À§ÇØ ÁøÇàÁßÀÔ´Ï´Ù. EV´Â À¯ÀüÀÚ ¹ßÇöÀ» Á¶ÀýÇØ ³ëÈ­ ¸¶Ä¿¸¦ °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ÒÆ÷´Â ÀüÀÓ»ó ¸ðµ¨¿¡¼­ ³ëÈ­ ¼¼Æ÷ÀÇ ºÎ´ãÀ» ÁÙÀÌ°í °Ç°­»óÀÇ Àü±Í¸¦ °³¼±ÇÒ °¡´É¼ºÀ» º¸¿©ÁÝ´Ï´Ù. ÀÌ·¯ÇÑ miRNA¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ±â¼ú Çõ½ÅÀÇ Áøº¸´Â ÇöÀç ÁøÇà ÁßÀÔ´Ï´Ù.

±â¼úÀû Áøº¸ÀÇ ÀÏȯÀ¸·Î ÀΰøÁö´É(AI)Àº »õ·Î¿î ¾ÈƼ¿¡ÀÌ¡ È­ÇÕ¹°ÀÇ ½Äº°¿¡ Çõ¸íÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù. µö ´º·² ³×Æ®¿öÅ© ½ºÅ©¸®´×°ú ÀǾàǰ °³¹ß È¿À²È­¸¦ Æ÷ÇÔÇÑ µÎ °¡Áö AI ÁÖµµÇü Á¢±Ù ¹æ½ÄÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ¼¼°è ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ¼¼³ë¸®Æ½½º ¾ÈƼ¿¡ÀÌ¡ ÀǾàǰÀÇ Çõ½Å, ½ÃÀå È®´ë ¹× ±ÔÁ¦ ÁøÀü¿¡ ÁßÁ¡À» µÎ°í ÀÖÀ½À» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : º¯µ¿ ¿äÀÎ, °æÇâ ¹× ¹üÀ§

Á¦4Àå ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : À¯Åë ä³Îº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå ¼¼³î¸®Æ½½º ¹× ³ëÈ­ ¹æÁö ÀǾàǰ ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®(Á¦Ç°º°, ¿ëµµº° ¹× À¯Åë ä³Îº°)

Á¦8Àå °æÀï ±¸µµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Senolytics And Anti-Aging Pharmaceuticals Market Growth & Trends:

The global senolytics and anti-aging pharmaceuticals market size is anticipated to reach USD 6.39 billion by 2030 and is anticipated to expand at a CAGR of 7.59% during the forecast period, according to a new report by Grand View Research, Inc.

Key drivers include increasing aging population and life expectancy, rising prevalence of non-communicable diseases such as Alzheimer's, Parkinson's, cancer, diabetes and osteoporosis seen in geriatric population. Growing awareness of anti-aging drugs and rising adoption of these senolytic pharmaceuticals boosts the services market growth. The market is further supported by strong research and development investments. Numerous pharmaceutical companies and academic institutions are investing in the development of senolytic therapies, advancing clinical trials, and expanding knowledge of how to effectively target senescent cells The market pipeline remains robust, with active research in gene therapies, stem cell therapeutics, and immunomodulators.

In February 2025, FOXO4-DRI Peptide a novel target for targeting senescence cells was found innovated. This synthetic peptide disrupts the interaction between FOXO4 and p53 proteins, leading to apoptosis of senescent cells. Studies in animal models have demonstrated its potential to alleviate age-related conditions such as renal failure and frailty. In vitro and in vivo studies were conducted for this novel target. These findings suggest that FOXO4-DRI holds therapeutic potential for targeting senescent cells and mitigating age-related pathologies.

In addition, another novel senescent cell targeting molecules were developed in February 2025 known as Proteolysis-targeting chimeras (PROTACs). These are bifunctional molecules that induce the degradation of specific proteins by recruiting them to E3 ligases, leading to ubiquitination and subsequent proteasomal degradation. In the context of cellular senescence, certain PROTACs have been developed to selectively eliminate senescent cells through mechanisms such as BCL-xL/BCL-2 degradation and BRD4 degradation. These highlight the therapeutic potential of PROTACs in selectively targeting and eliminating senescent cells, offering a promising strategy for treating age-related diseases and improving healthspan.

Furthermore, a thorough research on extracellular vesicles (EVs) and miRNA-Based Senolytics technology is ongoing for bringing drugs to clinical trials. EVs can modulate gene expression to reduce senescence markers. These vesicles have demonstrated potential in reducing senescent cell burden and improving health outcomes in preclinical models. Advances are ongoing for innovations in targeting these miRNAs.

As part of technological advancements, artificial intelligence (AI) is revolutionizing the identification of novel anti-aging compounds. Two AI-driven approaches are being developed that includes Deep neural network screening and enhanced drug development efficiencies.

These strategic initiatives underscore the growing emphasis on Senolytics and anti-aging pharmaceuticals innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Senolytics And Anti-Aging Pharmaceuticals Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Senolytics & Anti-Aging Pharmaceuticals Market Variables, Trends & Scope

Chapter 4. Senolytics & Anti-Aging Pharmaceuticals Market: Product Estimates & Trend Analysis

Chapter 5. Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Estimates & Trend Analysis

Chapter 6. Senolytics & Anti-Aging Pharmaceuticals Market: Application Estimates & Trend Analysis

Chapter 7. Senolytics & Anti-Aging Pharmaceuticals Market: Regional Estimates & Trend Analysis by Product, Application, and Distribution Channel

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â